Wall Street brokerages predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post sales of $4.91 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aclaris Therapeutics’ earnings, with the highest sales estimate coming in at $5.31 million and the lowest estimate coming in at $4.50 million. Aclaris Therapeutics posted sales of $1.00 million during the same quarter last year, which would indicate a positive year over year growth rate of 391%. The business is scheduled to announce its next quarterly earnings report on Monday, March 11th.

According to Zacks, analysts expect that Aclaris Therapeutics will report full-year sales of $11.27 million for the current year, with estimates ranging from $10.92 million to $11.61 million. For the next year, analysts expect that the firm will report sales of $52.18 million, with estimates ranging from $47.75 million to $56.60 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.19. The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%.

Several equities research analysts have issued reports on the company. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 17th. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday, December 21st. JMP Securities cut their target price on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a research note on Tuesday, October 16th. Finally, BidaskClub cut Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $39.35.

Shares of Aclaris Therapeutics stock traded down $0.04 during trading on Friday, hitting $7.15. The stock had a trading volume of 357,701 shares, compared to its average volume of 434,087. The company has a market cap of $302.52 million, a P/E ratio of -2.86 and a beta of 1.59. Aclaris Therapeutics has a 1 year low of $6.15 and a 1 year high of $26.25.

In other Aclaris Therapeutics news, Director Anand Mehra bought 372,093 shares of the business’s stock in a transaction dated Monday, October 22nd. The shares were purchased at an average price of $10.75 per share, with a total value of $3,999,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 17.00% of the company’s stock.

Large investors have recently made changes to their positions in the stock. FMR LLC grew its holdings in Aclaris Therapeutics by 31.1% during the 2nd quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock valued at $67,015,000 after purchasing an additional 796,805 shares in the last quarter. BlackRock Inc. raised its stake in Aclaris Therapeutics by 8.9% during the third quarter. BlackRock Inc. now owns 2,517,412 shares of the biotechnology company’s stock worth $36,551,000 after purchasing an additional 205,771 shares during the period. Citadel Advisors LLC raised its stake in Aclaris Therapeutics by 1.6% during the third quarter. Citadel Advisors LLC now owns 882,364 shares of the biotechnology company’s stock worth $12,812,000 after purchasing an additional 14,134 shares during the period. Bank of New York Mellon Corp raised its stake in Aclaris Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 423,001 shares of the biotechnology company’s stock worth $8,447,000 after purchasing an additional 31,339 shares during the period. Finally, Man Group plc raised its stake in Aclaris Therapeutics by 396.1% during the third quarter. Man Group plc now owns 402,624 shares of the biotechnology company’s stock worth $5,846,000 after purchasing an additional 321,458 shares during the period. 72.36% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Recommended Story: Front-End Load

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.